<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03497325</url>
  </required_header>
  <id_info>
    <org_study_id>ASUM hospital</org_study_id>
    <nct_id>NCT03497325</nct_id>
  </id_info>
  <brief_title>Effect of Autologous Platelet-rich Plasma in Uterine Wound Healing</brief_title>
  <official_title>the Efficacy of Intramuscular Autologous Platelet-rich Plasma Injection on Uterine Wound Healing After Primary Cesarean Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the efficacy of intramuscular autologus platelet rich&#xD;
      plasma on uterine wound healing after primary cesarean section&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      110 pregnant female undergoing primary prelabor CS will be randomized to two groups group&#xD;
      A)autologus PRP will be prepared from participant venous blood collected from the&#xD;
      participants' arm into a syringe primed with ACD-A. then it will be injected into uterus&#xD;
      after closing uterine incision . Injection sites will be selected near the incision at evenly&#xD;
      20 different sites&#xD;
&#xD;
      group B)normal saline 0.9 will be injected into uterus after closing uterine incision .&#xD;
      Injection sites will be selected near the incision at evenly 20 different sites.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Actual">December 15, 2020</completion_date>
  <primary_completion_date type="Actual">December 15, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of cesarean scar defect(niche)</measure>
    <time_frame>12 weeks after CS</time_frame>
    <description>any defect in the anterior myometrium related to scar site</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">134</enrollment>
  <condition>Cesarean Section Complications</condition>
  <arm_group>
    <arm_group_label>PRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>55 participant unergoing prelabor primary CS will receive intramyometrial injection of PRP after closure of uterine incision</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>55 participant unergoing prelabor primary CS will receive intramyometrial injection of normal saline after closure of uterine incision</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>autologus platelet rich plasma</intervention_name>
    <description>55 participant unergoing prelabor primary CS will receive intramyometrial injection of PRP after closure of uterine incision</description>
    <arm_group_label>PRP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>55 participant unergoing prelabor primary CS will receive intramyometrial injection of normal saline after closure of uterine incision</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Term pregnancy (gestational age between 37-41 weeks).&#xD;
&#xD;
          -  Women undergoing cesarean section for the first time.&#xD;
&#xD;
          -  Normal vaginal ultrasound examination and exclusion of any pelvic abnormality.&#xD;
&#xD;
          -  Uncomplicated cesarean section.&#xD;
&#xD;
          -  Lower uterine segment cesarean sections while the women not in labor&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women with complications during or after cesarean section as intrapartum or postpartum&#xD;
             hemorrhage, puerperal sepsis, septic wound&#xD;
&#xD;
          -  Women with medical diseases that can affect the healing as diabetes mellitus, anemia,&#xD;
             chronic renal disease or hepatic disease or coagulopathy or receiving medications&#xD;
             affect wound healing as corticosteroids or anticoagulant.&#xD;
&#xD;
          -  Women who will use intrauterine device as a contraceptive method Women with uterine&#xD;
             abnormality as cervical stenosis or fibroid uterus multiple gestation, placenta&#xD;
             abruption, placenta previa, antepartum hemorrhage prolonged ROM,&#xD;
             chorioamnionitis,meconium stained liquor&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ain Shams university maternity hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 6, 2018</study_first_submitted>
  <study_first_submitted_qc>April 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2018</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Radwa Rasheedy Ali</investigator_full_name>
    <investigator_title>lecturer</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

